Imanis Life Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Imanis Life Sciences's estimated annual revenue is currently $7.8M per year.
- Imanis Life Sciences's estimated revenue per employee is $155,000
Employee Data
- Imanis Life Sciences has 50 Employees.
- Imanis Life Sciences grew their employee count by 9% last year.
Imanis Life Sciences's People
Name | Title | Email/Phone |
---|
Imanis Life Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 50 | 9% | N/A | N/A |
#2 | $7.4M | 48 | -35% | N/A | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $0.3M | 2 | -91% | N/A | N/A |
#5 | $3.6M | 23 | 5% | N/A | N/A |
#6 | $0.9M | 6 | -33% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $14.7M | 95 | 9% | N/A | N/A |
#9 | $14.7M | 95 | 0% | $20.5M | N/A |
#10 | $27.9M | 144 | 13% | $39.1M | N/A |
What Is Imanis Life Sciences?
Imanis is a biotechnology company specializing in oncolytic virotherapy and non-invasive reporter gene imaging for cell and virus tracking. As a leader in in vivo imaging, we are committed to advancing these technologies in pre-clinical and clinical studies. We offer reagents and well-characterized viruses to support research in regenerative medicine, gene therapy, oncolytic virotherapy and oncology drug discovery.
keywords:N/AN/A
Total Funding
50
Number of Employees
$7.8M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Imanis Life Sciences News
Imanis Life Sciences based in Rochester has created a new test to track immunity to the omicron variant - for at-risk patients.
The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of...
The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.8M | 50 | 4% | N/A |
#2 | $8.2M | 50 | 9% | N/A |
#3 | $6.5M | 50 | 0% | N/A |
#4 | $6M | 50 | 11% | N/A |
#5 | $8.8M | 50 | 4% | N/A |